Search

Background: There is no study evaluating the use of glycated albumin (GA) for the detection of post-transplantation diabetes mellitus (PTDM) in kidney transplant recipients. We evaluated the overall accuracy of GA at four months after kidney transplantation., Methods: Diagnostic test accuracy study including 134 kidney transplant recipients without pre-existing diabetes. Receiver operator characteristic (ROC) curve was used to estimate sensitivity, specificity, likelihood ratios and area under the curve (AUC) for GA, considering oral glucose tolerance test (OGTT) and/or glycated hemoglobin (HbA1c) as reference criteria., Results: Thirty-three patients were diagnosed with PTDM by OGTT and/or HbA1c ≥ 6.5%. GA showed moderate accuracy to detect PTDM [AUC 0.673 (95% CI 0.557-0.789, p < 0.01)]. The use of OGTT and/or HbA1c ≥ 6.2% increased the number of PTDM cases from 33 to 38, and AUC was 0.713 (95% CI 0.608-0.819, p < 0.01). GA ≥ 17% showed specificity close to 90% when OGTT and/or HbA1c ≥ 6.5% were used as reference tests., Conclusions: GA showed low diagnostic accuracy for the detection of PTDM at the fourth month after transplantation. The use of a single GA point is not enough for the screening and diagnosis of PTDM; however, GA ≥ 17% presented high specificity to rule in the disease after kidney transplantation., (Copyright © 2020 Elsevier B.V. All rights reserved.)

We conducted a literature review about renal posttransplantation diabetes mellitus (PTDM), a glucose metabolism alteration with high incidence. Immunosuppressive therapy, by different diabetogenic mechanisms, is the major risk factor for PTDM. Although corticosteroids and calcineurin inhibitors are the drugs most related to PTDM, the mechanisms of other drugs have been also investigated. Available data in the literature show that, in renal transplant patients, the oral glucose tolerance test presents the highest diagnostic sensitivity for PTDM, although fasting plasma glucose is the most requested test. In addition, we also discussed the possible role of hemoglobin A1C in the diagnosis of PTDM. Renal PTDM is associated with patient survival reduction, increased cardiovascular mortality and has been linked to worsening graft function. As crucial as the screening, the accurate management of the disease can ameliorate graft and patient survival as well as the quality of life of this especial population. Several drugs have been studied in PTDM patients in order to achieve a better glycemic control and, in the best scenario, prevent PTDM. We present proper management approaches that should help to reduce the possible long-term consequences of PTDM., (Copyright © 2015 Elsevier B.V. All rights reserved.)

We carried out a systematic review and meta-analyses of studies that evaluated the possible effects of anemia, variant hemoglobin, and uremia on A1C levels in individuals without diabetes (DM). Medline and Embase were searched for studies that measured A1C values in groups with and without iron deficiency anemia (IDA) and/or iron deficiency (ID), variant hemoglobin and/or uremia by standardized methods. The difference between A1C levels in the groups with and without interferences was obtained by using random-effects meta-analysis and the effect size was presented as absolute difference of means (95% CI). Ten studies fulfilled the inclusion criteria, providing data from 11,176 participants without DM. There were no statistically significant differences in A1C in the presence of IDA/ID, HbS, and uremia by HPLC and uremia by immunoassay [0.79% (95% IC -0.39; 1.97), -0.13% (95% IC -0.51; 0.26), 0.15% (95% CI -0.58; 0.88) and -0.19% (95% CI -0.78; 0.40), respectively]. The effects of HbAS and uremia on A1C levels are within the expected individual variation and should not affect A1C results to diagnose DM. However, the effects of IDA/ID remain inconclusive and further studies are needed to clarify the glycation mechanisms in individuals with IDA/ID without diabetes., (Copyright © 2015 Elsevier B.V. All rights reserved.)

Background: The role of glycated hemoglobin (A1C) in the screening and diagnosis of posttransplantation diabetes mellitus (PTDM) is still not entirely understood. We evaluated the use of A1C test in renal transplant recipients at four months after transplantation., Methods: A total of 122 out of 274 patients without previous diabetes that underwent kidney transplantation were enrolled. ROC curve was used to analyze the performance of A1C to diagnose PTDM considering OGTT as the reference standard., Results: OGTT identified 32 (26.2%) patients with PTDM, whereas A1C≥6.5% (48 mmol/mol) identified only 16 patients. A1C showed moderate accuracy to detect PTDM in the ROC curve [AUC 0.832 (95% CI 0.740-0.924, p<0.001)]. A1C of 5.8% (40 mmol/mol) was the equilibrium point (sensitivity 75% and specificity 72.2%) and A1C≥6.2% (44 mmol/mol) showed high specificity of 93.3%., Conclusions: A1C≥6.5% (48 mmol/mol) is not enough to be used alone in the diagnosis of PTDM. The combined use of A1C cut-off points of ≤5.8% (40 mmol/mol) and ≥6.2% (44 mmol/mol) would reduce the number of OGTT by 85%. The use of an algorithm with A1C test in combination with FPG and/or 2h-PG proved to be the most efficient strategy to diagnose or rule out PTDM., (Copyright © 2015 Elsevier B.V. All rights reserved.)